MA30273B1 - Sel d'acide succinique de l'ester 1-{2-(2-chloro-4-{[(r)-2-hydroxy-2-oxo-1,2- dihydroquinolin-5-yl)methoxyphenylcarbamoyl)ethyl]piperidin-5-ylique de l'acide biphenyl-2-ylcarbamique et son utilisation pour le traitement de troubles pulmonaires. - Google Patents

Sel d'acide succinique de l'ester 1-{2-(2-chloro-4-{[(r)-2-hydroxy-2-oxo-1,2- dihydroquinolin-5-yl)methoxyphenylcarbamoyl)ethyl]piperidin-5-ylique de l'acide biphenyl-2-ylcarbamique et son utilisation pour le traitement de troubles pulmonaires.

Info

Publication number
MA30273B1
MA30273B1 MA31228A MA31228A MA30273B1 MA 30273 B1 MA30273 B1 MA 30273B1 MA 31228 A MA31228 A MA 31228A MA 31228 A MA31228 A MA 31228A MA 30273 B1 MA30273 B1 MA 30273B1
Authority
MA
Morocco
Prior art keywords
hydroxy
methoxyphenylcarbamoyl
dihydroquinolin
piperidin
oxo
Prior art date
Application number
MA31228A
Other languages
English (en)
French (fr)
Inventor
Reshma Chudasama
Andrew Kennedy
Leanda Jane Kindon
Franck Patrick Mallet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36119909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30273(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA30273B1 publication Critical patent/MA30273B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA31228A 2006-02-10 2008-09-10 Sel d'acide succinique de l'ester 1-{2-(2-chloro-4-{[(r)-2-hydroxy-2-oxo-1,2- dihydroquinolin-5-yl)methoxyphenylcarbamoyl)ethyl]piperidin-5-ylique de l'acide biphenyl-2-ylcarbamique et son utilisation pour le traitement de troubles pulmonaires. MA30273B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0602778.3A GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound

Publications (1)

Publication Number Publication Date
MA30273B1 true MA30273B1 (fr) 2009-03-02

Family

ID=36119909

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31228A MA30273B1 (fr) 2006-02-10 2008-09-10 Sel d'acide succinique de l'ester 1-{2-(2-chloro-4-{[(r)-2-hydroxy-2-oxo-1,2- dihydroquinolin-5-yl)methoxyphenylcarbamoyl)ethyl]piperidin-5-ylique de l'acide biphenyl-2-ylcarbamique et son utilisation pour le traitement de troubles pulmonaires.

Country Status (33)

Country Link
US (1) US7960551B2 (enExample)
EP (1) EP1981872B1 (enExample)
JP (1) JP5616021B2 (enExample)
KR (1) KR101488691B1 (enExample)
CN (1) CN101379057B (enExample)
AR (2) AR059409A1 (enExample)
AU (1) AU2007213767B2 (enExample)
BR (1) BRPI0707559B8 (enExample)
CA (1) CA2641769C (enExample)
CR (1) CR10227A (enExample)
CY (1) CY1119238T1 (enExample)
DK (1) DK1981872T3 (enExample)
EA (1) EA016580B1 (enExample)
ES (1) ES2640226T3 (enExample)
GB (1) GB0602778D0 (enExample)
HR (1) HRP20171304T1 (enExample)
HU (1) HUE034315T2 (enExample)
IL (1) IL193103A (enExample)
JO (1) JO3389B1 (enExample)
LT (1) LT1981872T (enExample)
MA (1) MA30273B1 (enExample)
MY (1) MY153656A (enExample)
NO (1) NO341343B1 (enExample)
NZ (1) NZ570242A (enExample)
PE (2) PE20110120A1 (enExample)
PL (1) PL1981872T3 (enExample)
PT (1) PT1981872T (enExample)
SG (1) SG169404A1 (enExample)
SI (1) SI1981872T1 (enExample)
TW (1) TWI401251B (enExample)
UA (1) UA100364C2 (enExample)
WO (1) WO2007090859A1 (enExample)
ZA (1) ZA200806782B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519138B2 (en) * 2009-04-14 2013-08-27 Glaxo Group Limited Process for the preparation of a biphenyl-2-yl carbamic acid ester
ES2635358T3 (es) * 2009-04-23 2017-10-03 Theravance Respiratory Company, Llc Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
PH12014500193A1 (en) * 2011-08-02 2014-03-24 Alfasigma Spa Pharmaceutical composition of oxidised avidin suitable for inhalation
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ES2750523T3 (es) * 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026897A (en) 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4894219A (en) 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
EP0640081B1 (en) 1992-03-31 2000-01-12 Glaxo Group Limited Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-ht4 antagonists
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
AU685225B2 (en) 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
ATE205490T1 (de) 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
CA2313125A1 (en) 1997-12-12 1999-06-24 Laramie Mary Gaster Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
AU763638B2 (en) 1998-06-08 2003-07-31 Theravance Biopharma R&D Ip, Llc Muscarinic receptor antagonists
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
ATE299494T1 (de) 1999-12-07 2005-07-15 Theravance Inc Carbamat-derivate als muscarin-rezeptor antonisten
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
CN1471515A (zh) 2000-06-05 2004-01-28 ��̹��ҽҩ��˾ 作为β2-肾上腺素受体激动剂及PDE-4抑制剂的有效的化合物
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
RS50735B (sr) 2002-04-12 2010-08-31 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Medikamenti koji sadrže betamimetik lekove i novi lek antiholinesteraze
EP1507754A1 (en) 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
ES2329133T3 (es) 2003-05-28 2009-11-23 Theravance, Inc. Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos.
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物

Also Published As

Publication number Publication date
SI1981872T1 (sl) 2017-10-30
CA2641769A1 (en) 2007-08-16
TWI401251B (zh) 2013-07-11
CR10227A (es) 2008-10-29
BRPI0707559B1 (pt) 2021-01-12
JP5616021B2 (ja) 2014-10-29
EA200801691A1 (ru) 2009-02-27
EA016580B1 (ru) 2012-06-29
CA2641769C (en) 2014-02-04
CY1119238T1 (el) 2018-02-14
BRPI0707559A8 (pt) 2019-01-29
NO20083425L (no) 2008-09-09
IL193103A (en) 2013-06-27
US20070281971A1 (en) 2007-12-06
BRPI0707559B8 (pt) 2021-05-25
PT1981872T (pt) 2017-09-13
AR104288A2 (es) 2017-07-12
SG169404A1 (en) 2011-03-30
WO2007090859A1 (en) 2007-08-16
US7960551B2 (en) 2011-06-14
PL1981872T3 (pl) 2017-11-30
BRPI0707559A2 (pt) 2011-05-10
CN101379057B (zh) 2013-02-13
EP1981872B1 (en) 2017-06-21
PE20071249A1 (es) 2008-01-16
LT1981872T (lt) 2017-09-11
AU2007213767B2 (en) 2012-04-26
ZA200806782B (en) 2009-10-28
PE20110120A1 (es) 2011-03-08
UA100364C2 (xx) 2012-12-25
KR101488691B1 (ko) 2015-02-02
EP1981872A1 (en) 2008-10-22
KR20080114723A (ko) 2008-12-31
HUE034315T2 (en) 2018-02-28
AR059409A1 (es) 2008-04-09
JO3389B1 (ar) 2019-03-13
NO341343B1 (no) 2017-10-16
AU2007213767A1 (en) 2007-08-16
MY153656A (en) 2015-03-13
DK1981872T3 (en) 2017-09-11
JP2009526018A (ja) 2009-07-16
IL193103A0 (en) 2009-02-11
CN101379057A (zh) 2009-03-04
TW200800948A (en) 2008-01-01
NZ570242A (en) 2011-09-30
HRP20171304T1 (hr) 2017-10-20
ES2640226T3 (es) 2017-11-02
GB0602778D0 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
MY153656A (en) Succinc acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl) ethylamino]methyl]}-5-methoxyphenylcarbamyl)ethyl]piperidin-4-yl ester and its use for the treatment of pulmonary disorders
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
TW200613296A (en) Crystalline form of a biphenyl compound
EP4255429A4 (en) 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists
FR19C1005I2 (fr) Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation
EP2149047A4 (en) POLYMORPHISMS IN GENES WITH INFLUENCE ON DOPAMINTRANSPORTER DISEASES AND ITS APPLICATIONS
MA28084A1 (fr) Formes polymorphes de 3-(4-amino-1-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione
MA38071B1 (fr) Formes cristallines d'un inhibiteur de facteur xia
EP1644039A4 (en) COMPOSITIONS AND METHOD FOR TREATING COOLING DISORDER
ATE328879T1 (de) Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
MA29451B1 (fr) Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme
MX2010004501A (es) Inhibidor de la proteina de activacion de 5-lipoxigenasa (plap).
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
WO2008050199A8 (en) Substituted phenylmethyl bicyclocarboxyamide compounds
EP2004164A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DEGENERATIVE AND INFLAMMATORY DISEASES
BR0317968A (pt) Composições oftálmicas comtendo loratadina
EP2020445A4 (en) DETECTION OF INFLAMMATORY DISEASE AND COMPOSITION FOR PREVENTING OR TREATING AN INFLAMMATORY DISEASE
EP1496721A3 (en) Flat display apparatus
FR2911609B1 (fr) Copolymere dibloc comprenant des unites derivant du styrene et des unites derivant d'acide acrylique
FI20060247L (fi) Bakteeri-itiöiden muodostumisen estäminen kartonkikoneen hylkysysteemissä
MA27730A1 (fr) Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl-)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete
FR2889068B1 (fr) Nouvelles fractions proteiques laitieres et leur utilisation pour la prevention ou le traitement des maladies inflammatoires chroniques
EA201070361A1 (ru) Полиморфные разновидности (s)-2-((4-бензофуранил)карбониламинометил)-1-((4-(2-метил-5-(4-фторфенил))тиазолил)карбонил)пиперидина
MX2009005739A (es) Derivado piperidinico utilizado para tratar enfermedades mediadas por el receptor 5 de quimiocina.
WO2007049303A3 (en) An improved process for the preparation of highly pure fexofenadine